These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 11034097)

  • 61. Characterization of BAX inhibitor-1 as a novel leukemia-associated antigen.
    Schmidt SM; König T; Bringmann A; Held S; von Schwarzenberg K; Heine A; Holderried TA; Stevanovic S; Grünebach F; Brossart P
    Leukemia; 2009 Oct; 23(10):1818-24. PubMed ID: 19609282
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells.
    Feldmann A; Arndt C; Töpfer K; Stamova S; Krone F; Cartellieri M; Koristka S; Michalk I; Lindemann D; Schmitz M; Temme A; Bornhäuser M; Ehninger G; Bachmann M
    J Immunol; 2012 Sep; 189(6):3249-59. PubMed ID: 22875801
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587.
    Li B; Wang Y; Chen J; Wu H; Chen W
    Clin Exp Immunol; 2005 May; 140(2):310-9. PubMed ID: 15807856
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
    Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S
    Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.
    Zhang S; Zhang HS; Reuter VE; Slovin SF; Scher HI; Livingston PO
    Clin Cancer Res; 1998 Feb; 4(2):295-302. PubMed ID: 9516914
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer.
    Matera L
    Cancer Treat Rev; 2010 Apr; 36(2):131-41. PubMed ID: 19954892
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide.
    Inoue Y; Takaue Y; Takei M; Kato K; Kanai S; Harada Y; Tobisu K; Noguchi M; Kakizoe T; Itoh K; Wakasugi H
    J Urol; 2001 Oct; 166(4):1508-13. PubMed ID: 11547122
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Small interference RNA-mediated silencing of prostate stem cell antigen attenuates growth, reduces migration and invasion of human prostate cancer PC-3M cells.
    Zhao Z; Ma W; Zeng G; Qi D; Ou L; Liang Y
    Urol Oncol; 2013 Apr; 31(3):343-51. PubMed ID: 21429770
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells.
    Arndt C; Feldmann A; Töpfer K; Koristka S; Cartellieri M; Temme A; Ehninger A; Ehninger G; Bachmann M
    Prostate; 2014 Sep; 74(13):1347-58. PubMed ID: 25053504
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma.
    Komohara Y; Harada M; Arima Y; Suekane S; Noguchi M; Yamada A; Itoh K; Matsuoka K
    Int J Oncol; 2006 Dec; 29(6):1555-60. PubMed ID: 17088996
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.
    Yamada A; Kawano K; Koga M; Matsumoto T; Itoh K
    Cancer Res; 2001 Sep; 61(17):6459-66. PubMed ID: 11522641
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Decreased HLA-A expression in prostate cancer is associated with normal allele dosage in the majority of cases.
    Lu QL; Abel P; Mitchell S; Foster C; Lalani EN
    J Pathol; 2000 Feb; 190(2):169-76. PubMed ID: 10657015
    [TBL] [Abstract][Full Text] [Related]  

  • 73. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.
    Correale P; Walmsley K; Nieroda C; Zaremba S; Zhu M; Schlom J; Tsang KY
    J Natl Cancer Inst; 1997 Feb; 89(4):293-300. PubMed ID: 9048833
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival.
    Thomas-Kaskel AK; Zeiser R; Jochim R; Robbel C; Schultze-Seemann W; Waller CF; Veelken H
    Int J Cancer; 2006 Nov; 119(10):2428-34. PubMed ID: 16977630
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma.
    Inoda S; Hirohashi Y; Torigoe T; Nakatsugawa M; Kiriyama K; Nakazawa E; Harada K; Takasu H; Tamura Y; Kamiguchi K; Asanuma H; Tsuruma T; Terui T; Ishitani K; Ohmura T; Wang Q; Greene MI; Hasegawa T; Hirata K; Sato N
    J Immunother; 2009 Jun; 32(5):474-85. PubMed ID: 19609239
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Wildtype p53-specific antibody and T-cell responses in cancer patients.
    Pedersen AE; Stryhn A; Justesen S; Harndahl M; Rasmussen S; Donskov F; Claesson MH; Pedersen JW; Wandall HH; Svane IM; Buus S
    J Immunother; 2011; 34(9):629-40. PubMed ID: 21989411
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Identification of noncanonical melanoma-associated T cell epitopes for cancer immunotherapy.
    Bredenbeck A; Losch FO; Sharav T; Eichler-Mertens M; Filter M; Givehchi A; Sterry W; Wrede P; Walden P
    J Immunol; 2005 Jun; 174(11):6716-24. PubMed ID: 15905511
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells.
    Lee HM; Timme TL; Thompson TC
    Cancer Res; 2000 Apr; 60(7):1927-33. PubMed ID: 10766182
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.
    Simons BW; Cannella F; Rowley DT; Viscidi RP
    Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
    Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
    J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.